These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 8235703)
21. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732 [TBL] [Abstract][Full Text] [Related]
22. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ; Kast WM Immunol Rev; 1995 Jun; 145():167-77. PubMed ID: 7590825 [No Abstract] [Full Text] [Related]
23. An antigen-targeted approach to adoptive transfer therapy of cancer. Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604 [TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy for unresectable pancreatic cancer]. Yahara N; Oka M Gan To Kagaku Ryoho; 2002 Mar; 29(3):390-7. PubMed ID: 11915728 [TBL] [Abstract][Full Text] [Related]
25. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Becker C; Pohla H; Frankenberger B; Schüler T; Assenmacher M; Schendel DJ; Blankenstein T Nat Med; 2001 Oct; 7(10):1159-62. PubMed ID: 11590442 [TBL] [Abstract][Full Text] [Related]
26. gammadelta T cells: a new frontier for immunotherapy? Lamb LS; Lopez RD Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234 [TBL] [Abstract][Full Text] [Related]
27. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL]. Masaki Y; Oka M Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044 [TBL] [Abstract][Full Text] [Related]
28. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925 [TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Hambach L; Goulmy E Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682 [TBL] [Abstract][Full Text] [Related]
30. How much help does a vaccine-induced T-cell response need? Weber JS; Mulé JJ J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555 [No Abstract] [Full Text] [Related]
32. Considerations on clinical use of T cell immunotherapy for cancer. Plautz GE; Cohen PA; Shu S Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434 [TBL] [Abstract][Full Text] [Related]
33. Suicide genes as safety switches in T lymphocytes. Straathof KC; Spencer DM; Sutton RE; Rooney CM Cytotherapy; 2003; 5(3):227-30. PubMed ID: 12850790 [TBL] [Abstract][Full Text] [Related]
35. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. Libutti SK Cancer Gene Ther; 2015 Mar; 22(2):63. PubMed ID: 25753044 [No Abstract] [Full Text] [Related]
36. European Organization for Research and Treatment of Cancer Workshop. Problems and prospects in current therapeutic application of molecular biology. McVie JG; Muggia FM Cancer Res; 1987 Jun; 47(11):3032. PubMed ID: 3567917 [No Abstract] [Full Text] [Related]
37. Immunotherapy for HIV infection. Lancet; 1993 Jan; 341(8838):171. PubMed ID: 8093761 [No Abstract] [Full Text] [Related]